TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04395248
Drug: Type of volatile anesthetics and M-Entropy guidance of anesthesia depth
Normalized name: Betagen brand of Betamethasone and Gentamicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the operating room, a M-Entropy™ sensor and S/5™ module (GE Healthcare, Helsinki, Finland) will be applied to all patients' forehead before induction of anesthesia according to the manufacturer's recommendations. Patients will be randomized to Sevoflurane or Desflurane as the single volatile anesthetics for general anesthesia.~Besides, patients will be randomized to M-Entropy group or controls. In the M-Entropy group, dosage of volatile anesthetics will be adjusted to achieve the Response and State Entropy value between 40 and 60 from the start of anesthesia to the end of surgery. In the usual care group, dosage of volatile anesthetics will be titrated according to clinical judgment. M-Entropy monitoring will be continued in the usual care group, but the Entropy number and EEG waveform will be concealed from the anesthetist in charge.
Study: NCT02965664
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drops contain the same ingredients as PresbiDrops except for the active ingredients
Study: NCT04316325
Drug: Medical abortion
Normalized name: ABSORPTION BASE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trained abortion providers will counsel participants about medical abortion via videoconference or telephone, the abortion medications will be sent to the participants via mail or will be accessed at a pharmacy, the provider will follow up one week later with the participants to assess outcomes, and four weeks later the participant will take a pregnancy test to confirm completion of the abortion
Study: NCT01520545
Drug: Gablofen® 3 mg/mL (baclofen injection)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is a prospective twelve-month Phase IIIb clinical safety trial followed by a 2-year, Phase IV study that will be conducted at clinical trial sites that are experienced with the use of intrathecal baclofen. Patients will be followed for the duration of their treatment with Gablofen® (baclofen injection) 3 mg/mL using the SynchroMed® II Programmable Pump or until the study is terminated.
Study: NCT01494103
Drug: AP1903
Approvals — FDA: no, EMA: no, PMDA: no
Description: AP1903 will be administered if there is development of Grade 1 or greater GvHD.~Dose: 0.4 mg/kg by IV over 2 hours.~Up to 3 additional doses may be administered if the GvHD does not respond or gets worse.
Study: NCT02293460
Drug: I10E
Normalized name: SET,INFUSION ACCU-CHEK ULTRAFLEX-I10-110
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who meet all eligibility criteria will receive one dose of IMP at 2g/kg over 2-5 days followed by 7 doses of IMP at 1g/kg over 1-2 day(s), every 3 weeks.~Duration of treatment period: 21 weeks +/- 7 days.
Study: NCT01185860
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral doses
Study: NCT02145624
Drug: Repevax
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaccine
Study: NCT00354562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo daily for 14 days every 21 days
Study: NCT01074008
Drug: ABT-450
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg capsules co-administered with ritonavir
Study: NCT01074008
Drug: ABT-333
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg tablet
Study: NCT01665651
Drug: Yougui granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yougui granules is traditional Chinese patent medicine used to treatment patients with kidney Yang deficiency. Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
Study: NCT01665651
Drug: Zuogui granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zuogui granules is traditional Chinese patent medicine used to treatment patients with kidney Yin deficiency. Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
Study: NCT01665651
Drug: Yougui granules placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
Study: NCT01665651
Drug: Zuogui granules placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
Study: NCT03577886
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphate Buffer Diluent oral solution
Study: NCT02121041
Drug: Chlorthalidone
Normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone 12.5 mg or 25 mg
Study: NCT02788513
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01577056
Drug: HMG Coenzyme reductase
Approvals — FDA: no, EMA: no, PMDA: no
Description: All FH subjects are on standard statin treatment during study period
Study: NCT03907241
Drug: Octanorm 16.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human normal immunoglobulin
Study: NCT03018509
Drug: JTE-451
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active drug tablets containing JTE-451
Study: NCT01280344
Drug: Saline Solution for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV)
Study: NCT02938442
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects randomized to the chemo+vaccine arm will be immunized with P10s-PADRE in MONTANIDE™ ISA 51 VG a total of three times. The vaccine will be administered on weeks 1, 2 and 3 prior to chemotherapy. Then, they will start their SoC neoadjuvant chemotherapy on week 4. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
Study: NCT03018509
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets identical in appearance to the active drug tablets
Study: NCT02938442
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Subjects randomized to the chemo+vaccine arm will be immunized with P10s-PADRE in MONTANIDE™ ISA 51 VG a total of three times. The vaccine will be administered on weeks 1, 2 and 3 prior to chemotherapy. Then, they will start their SoC neoadjuvant chemotherapy on week 4. Doxorubicin and cyclophosphamide (AC) will be administered concurrently every two weeks for four cycles with pegfilgrastim (or equivalent growth factor) on day 2 of each AC cycle, followed by paclitaxel weekly x 12 weeks.
Study: NCT00005094
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT01730040
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin over-encapsulated tablets orally.
Study: NCT01730040
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo for alirocumab and ezetimibe.
Study: NCT02854696
Drug: best medical care
Normalized name: benzethonium Medicated Liquid Soap [Bedside-Care]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will continue their insulin treatment
Study: NCT03449199
Drug: TMX-049
Approvals — FDA: no, EMA: no, PMDA: no
Description: A certain dose of TMX-049 to be taken orally, once daily
Study: NCT03449199
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to be taken orally, once daily
Study: NCT01385826
Drug: Anti-tumor necrosis factor alpha monoclonal antibody
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of adalimumab will be 40 mg for children age 13 and over and for children younger than 13 adalimumab 24 mg per m2 BSA (up to a maximum total body dose of 40 mg).
Study: NCT01385826
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive 4 injections of placebo on D0, D14, D28, and D42 with assessment of the primary endpoint at M2
Study: NCT02622659
Drug: Fuganlin Oral Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: less than 1 years old: 5mL each time and three times a day~1\~3 years old: 10mL each time and three times a day~4\~6 years old: 10mL each time and four times a day~7\~12 years old: 10mL each time and five times a day
Study: NCT02622659
Drug: Xiaoer Jiebiao Oral Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1\~2 years old: 5mL each time and twice a day~3\~5 years old: 5mL each time and three times a day~6\~14 years old: 10mL each time and twice a day
Study: NCT00035321
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00666887
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg twice daily to be taken for up to 2 years
Study: NCT00666887
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo twice daily for 2 years
Study: NCT02588820
Drug: Antiretroviral Therapy (Experimental)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Initial ART until HLA-B5701 results became available (48 hours):~   1. Tenofovir 245 mg once a day~  2. Emtricitabine 200 mg once a day~  3. Dolutegravir 50 mg once a day~  4. Darunavir 800 mg once a day~  5. Ritonavir 100 mg once a day~  6. Maraviroc 150 mg twice a day~2. Three months continuation treatment (after HLA-B5701 confirmed as negative):~   1. Dolutegravir 50 mg once a day.~  2. Abacavir 600 mg once a day~  3. Lamivudine 300 mg once a day~  4. Darunavir 800 mg once a day~  5. Ritonavir 100 mg once a day~  6. Maraviroc 150 mg twice a day The whole treatment schedule comprises 7 pills per day (in a single dose), except for maraviroc, which will be given twice daily.~3. Nine months continuation treatment (till complete 12 months treatment):~   1. Abacavir, 600mg once a day~  2. Lamivudine, 300 mg once a day~  3. Dolutegravir, 50 mg once a day
Study: NCT01701973
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: During Aim 1, given on one of two study days (other study day subjects receive sitagliptin.) During Aim 2, given on one of two study days (other study day subjects receive either L-NMMA, pegvisomant, or Exendin 9-39 pending their group assignment)
Study: NCT02904538
Drug: isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01677208
Drug: Danhong injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: A kind of injection made from two kind of Chinese herbs: Salvia miltiorrhiza and Safflower. 40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
Study: NCT01677208
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
Study: NCT03808740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sugar pill
Study: NCT00471991
Drug: Ethinyl estradiol / dienogest (SH D00659 AF)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study consists of 4 cycles resulting in approx. 16 weeks of study participation. The investigational product is an oral contraceptive. 21 tablets are taken each cycle followed by a 7-day tablet-free interval. (One cycle lasts for 28 days.)Volunteers will have to come for a visit every 2 to 4 days over the whole study period.The function of the ovaries is studied by transvaginal ultrasonography and determination of hormonal parameters from blood samples. The mouth of the uterus is inspected during each visit and the cervical smear will be investigated. Adverse events will be recorded and diary entries will be controlled by the investigator.Volunteers have to undergo a series of blood sampling during the 2nd treatment cycle to evaluate the pharmacokinetic (liberation, absorption, distribution, metabolization and excretion) of the new oral contraceptive.
Study: NCT02363439
Drug: IMO-8400 0.6 mg/kg/wk or 1.2 mg/kg twice weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMO-8400 at 0.6 mg/kg/wk or 1.2 mg/kg twice weekly as defined per Protocol 8400-401
Study: NCT02023840
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00551616
Drug: CDB-2914
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose
Study: NCT03946917
Drug: JS001
Normalized name: Janus Kinase Inhibitor JS001
Approvals — FDA: no, EMA: no, PMDA: no
Description: JS001 3 mg/kg, iv drip, d1, d15, q4w
Study: NCT01854255
Drug: doxorubicin and cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: doxorubicin and cisplatin as intraperitoneal chemotherapy
Study: NCT02010255
Drug: LDV/SOF
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDV/SOF FDC tablet administered orally once daily
Study: NCT01134627
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants who are self-administering Rebif® (IFN beta-1a) 44 microgram (mcg) as subcutaneous (sc) injection thrice weekly will also receive minocycline 100 milligram (mg) tablet twice daily as an add-on therapy in accordance with clinical practice for 96 weeks.
Study: NCT01134627
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants who are self-administering Rebif® (IFN beta-1a) 44 mcg as sc injection thrice weekly will also receive placebo tablets twice daily for 96 weeks.
Study: NCT00508027
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Comparison of 3 dosages of simvastatin given in a dose-escalating fashion. 20 mg, 40 mg, or 80 mg PO QD x 21 days followed by a drug taper x 4 days.
Study: NCT01275157
Drug: LY2452473
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally as a liquid suspension
Study: NCT03668431
Drug: PDR001
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDR001 will be administered IV every 28 days
Study: NCT00977431
Drug: BIBW2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating dose cohorts during Radiotherapy(RT) period, fixed dose after RT
Study: NCT00977431
Drug: BIBW2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalating dose cohorts during Radiotherapy(RT) period , fixed dose after RT
Study: NCT05369091
Drug: Simvastatin 10mg
Normalized name: SIMVASTATIN 10MG TAB
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atraumatic Extraction and administration of SIM (10 mg tablet grounded and added with normal saline, with gelatin sponge as a transporter) into the socket to observe alveolar bone healing.
Study: NCT01876368
Drug: LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01876368
Drug: Placebo of LCZ696
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01391845
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo orally in a unique dose the day of hCG injection
Study: NCT02563769
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered orally in capsules identical to CLAV and be filled with crystalline microcellulose
Study: NCT02078921
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00689845
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00689845
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT00689845
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00689845
Drug: prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given orally
Study: NCT01661634
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00656968
Drug: 10-day sequential treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: esomeprazole (40 mg daily) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 5, clarithromycin (500 mg, bid) from day 6 to day 10, metronidazole (500 mg, bid) from day 6 to day 10
Study: NCT00656968
Drug: 10-day concomitant therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: esomeprazole (40 mg, bid) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 10, clarithromycin (500 mg, bid) from day 1 to day 10, metronidazole (500 mg, bid) from day 1 to day 10
Study: NCT01246713
Drug: Acetaminophen solid formulation
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
Study: NCT04686994
Drug: ASC 41 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT00190489
Drug: AC (ADM 40mg/m2+CPA 500mg/m2) q21 days x 6 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00115024
Drug: Micronized 17B-estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02079337
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00109486
Drug: GW685698X
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00932724
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampoules with 1 ml placebo solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks
Study: NCT00707421
Drug: ketorolac acetate
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01168687
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04628936
Drug: KZR-616
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous 30 mg for 1 week, then 45 mg weekly
Study: NCT01118026
Drug: BEACOPP
Approvals — FDA: no, EMA: no, PMDA: no
Description: bleomycin 10 units/m\^2 IV on Day 8 etoposide 200 mg/m\^2 IV on Days 1, 2 and 3 doxorubicin 35 mg/m\^2 IV on Day 1 cyclophosphamide 1250 mg/m\^2 IV on Day 1 vincristine 1.4 mg/m\^2 IV on Day 8 procarbazine 100 mg/m\^2 orally on Days 1-7 prednisone 40 mg/m\^2 orally on Days 1-14
Study: NCT00148720
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taken orally twice a day for 14 days and treatment will repeat every 21 days (1 cycle) for 4 cycles
Study: NCT06677853
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects were applied with placebo at the affected area 3 times a day for 24 weeks.
Study: NCT04253353
Drug: rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg tablet
Study: NCT00648245
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo given once daily for 21 days by nebulizer
Study: NCT01471834
Drug: Medical Management
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05149924
Drug: QL1012
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection,starting dose within 75IU \~ 300IU determined by the age , maximum daily dose 450IU
Study: NCT05149924
Drug: Gonal-f ®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection,starting dose within 75IU \~ 300IU determined by the age , maximum daily dose 450IU
Study: NCT03936218
Drug: Inj. Zoladex (Reference) Subcutaneously
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10.8 mg, Subcutaneously at every 3 month
Study: NCT03965728
Drug: BAY1830839
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral.
Study: NCT03965728
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral.
Study: NCT03965728
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Only for Dose 3 step. Tablet, oral. Two single doses. One dose administered during pre-dose in Period 1 and the second dose administered on the last day of treatment with BAY1830839 or placebo in Period 2.
Study: NCT01478828
Drug: Lovastatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral qd varying dose escalations/de-escalations
Study: NCT01789957
Drug: AC2993
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-Week transition of AC2993 5 mcg subcutaneously injected twice daily followed by an open-ended period through study termination (up to 52 weeks) of AC2993 10 mcg subcutaneously injected twice daily
Study: NCT02265406
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01961882
Drug: OCV-501
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01961882
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00715091
Drug: diclophenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous (daily) treatment of diclofenac cholestyramine 150 mg, divided into 75mg twice daily
Study: NCT00715091
Drug: diclophenac
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment on-demand (as needed) with diclofenac-cholestyramine 75 to 150 mg daily
Study: NCT04493476
Drug: Chinese herbal formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbal formula
Study: NCT04664816
Drug: Placebo Treatment
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo orally, twice a day for at least 12 months.
Study: NCT03009487
Drug: Olmesartan 40 mg, Rosuvastatin 20mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Crestor tab. 20mg(Rosuvastatin 20mg) and placebo of Sevikar Tab 10/40mg(Amlodipine/Olmesartan 10/40mg).
Study: NCT01647958
Drug: PPI
Normalized name: PPIase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Arm participants will take maximum standard dose of PPI during Initial Study period
Study: NCT03785145
Drug: MT10109L
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT10109L will be injected into the LCL.
Study: NCT03785145
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be injected into the LCL.
Study: NCT00643734
Drug: azithromycin sustained release
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azithromycin SR 2.0 g by mouth in the form of a slurry for 1 dose
Study: NCT04591652
Drug: 99mTc-MIRC208
Approvals — FDA: no, EMA: no, PMDA: no
Description: 99mTc-MIRC208 SPECT/CT: after intravenous injection of 14.8 MBq/kg body weight of quality-controlled 99mTc-MIRC208 2 h, a Siemens Symbia T16 SPECT/CT scan will be performed within 1 h.
Study: NCT02970552
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indistinguishable placebo vaginal suppository
Study: NCT00407745
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo